Last reviewed · How we verify

Oxytocin Substitution Therapy in Patients With AVP Deficiency (Central Diabetes Insipidus) (OxyTUTION)

NCT06036004 Phase 2 RECRUITING

This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (± 2 days) (one additional visit)

Details

Lead sponsorUniversity Hospital, Basel, Switzerland
PhasePhase 2
StatusRECRUITING
Enrolment112
Start date2024-01-08
Completion2026-10

Conditions

Interventions

Primary outcomes

Countries

Germany, Netherlands, Switzerland